证券研究报告：医药生物|点评报告 发布时间：2026-01-05 行业投资评级 强于大市 |维持 行业基本情况 | 收盘点位 | | 8084.61 | | --- | --- | --- | | 52 | 周最高 | 9323.49 | | 52 | 周最低 | 6764.34 | 行业相对指数表现（相对值） 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 近期研究报告 《国内创新药研发景气回暖，关注非临 床安评行业投资机会》 - 2025.12.29 病理价格精细化政策落地，利好数字化医疗新基建 点评：此次《指南》的颁布标志着我国病理医疗服务进入标准化、 规范化、数字化协同发展的新阶段。作为疾病诊断的"金标准"，病理 诊断的精准度与效率直接影响临床决策质量和患者预后，此次政策的 出台更彰显了国家提升病理服务可及性、推动医疗资源优化配置的决 心，也为深耕病理领域的企业提供了明确的发展方向与实践路径。 政策特别强调了数字化技术在病理诊断中的应用价值，为数字化 切片、远程诊断、智能分析等新型服务模式的推广提供了政策支撑， 有望加速病 ...

Core Insights - The National Healthcare Security Administration has officially issued the "Guidelines for the Project Establishment of Pathology Medical Service Pricing (Trial)" which marks a new phase of standardized, regulated, and digital collaborative development in China's pathology medical services [1][2] Group 1: Policy Overview - The guidelines consolidate existing pathology medical service pricing projects into 28 core items, 3 additional charge items, and 2 expansion items, creating a clearer pricing framework [2] - The National Healthcare Security Administration will guide provinces to establish a unified price benchmark, allowing regions to adjust actual execution prices based on this benchmark [2] Group 2: Digital Transformation - The policy emphasizes the application value of digital technology in pathology diagnosis, supporting the promotion of new service models such as digital slides, remote diagnosis, and intelligent analysis [3] - This shift is expected to accelerate the transition of pathology from traditional manual operations to a fully digital process, making pathology data an important "data asset" in medical services [3] Group 3: Beneficiary Companies - Companies like Anbiping, which has automated workstations for specimen processing and supports digital slide applications, are well-positioned to benefit from this policy [4] - Aide Biology focuses on precision medical conditions and has developed an automated reporting and data management system, enhancing its capabilities in pathology services [4] - Zhongyuan Qihua provides comprehensive solutions for major diseases, integrating equipment, reagents, and services to support clinical medical institutions [4] - Maike Biology specializes in providing reagents, equipment, and technical support for pathology diagnosis, aiming for automation and intelligence in laboratory processes [4] - Other companies in the ICL category include Jinyu Medical, Dean Diagnostics, Lanwei Medical, and Aide Kang, which are also expected to benefit from the policy [4]